RCUS Company Profile and Key Details

Q: Who are the executives of RCUS?

Dr. Jonathan Yingling Ph.D.Chief Scientific OfficerDr. Juan Carlos Jaen Ph.D.Co-Founder, Pres & DirectorDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific AdvisorDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific AdvisorHolli KolkeyVice President of Corporation CommunicationsDr. Stephen Young Ph.D.Senior Vice President of Technology & Quantitative BiologyMr. Robert C. Goeltz IIPrincipal Financial Officer & Chief Financial OfficerDr. Terry J. Rosen Ph.D.Co-Founder, Chairman & Chief Executive OfficerMs. Jennifer A. Jarrett M.B.A.Chief Operating Officer & DirectorMs. Carolyn C. Tang J.D.Gen. Counsel & Corporation Sec.Ms. Katherine BockVice President of Investor Relations & Corporation StrategyDr. Dimitry S.A. Nuyten M.D., Ph.D.Chief Medical OfficerMr. Alexander AzoyChief Accounting Officer & Principal Accounting Officer

NYSE : RCUS

Arcus Biosciences

$23.20

-0.5-2.11%

Open: 1:41 PM

58.67

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Arcus Biosciences, Inc. (RCUS) stock declined over -2.11%, trading at $23.20 on NYSE, down from the previous close of $23.70. The stock opened at $23.60, fluctuating between $22.96 and $23.74 in the recent session.

Stock Snapshot

23.7

Prev. Close

2.34B

Market Cap

22.96

Day Low

-7.05

P/E Ratio

-3.29

EPS (TTM)

-4.4

Cash Flow per Share

23.6

Open

100.67M

Number of Shares

23.7445

Day High

56.27%

Free Float in %

6.16

Book Value

300.34K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	22.52	23.09	22.47	23.01	660.42K
Apr 13, 2026	22.43	23.13	22.07	22.39	755.11K
Apr 10, 2026	23.41	23.41	22.27	22.34	590.56K
Apr 09, 2026	22.37	23.39	22.31	23.28	565.75K
Apr 08, 2026	22.70	23.17	22.17	22.65	1.06M
Apr 07, 2026	22.15	22.32	21.59	22.07	714.18K
Apr 06, 2026	22.92	23.17	22.15	22.24	655.03K
Apr 02, 2026	21.95	23.45	21.52	22.96	1.58M
Apr 01, 2026	22.07	22.67	21.60	21.84	1.32M
Mar 31, 2026	21.24	22.09	21.24	21.60	1.46M
Mar 30, 2026	20.27	20.96	20.00	20.65	718.2K
Mar 27, 2026	21.31	21.68	20.24	20.28	734.65K
Mar 25, 2026	20.63	21.83	20.63	21.46	847.11K
Mar 24, 2026	20.75	20.98	20.15	20.25	1.45M
Mar 23, 2026	21.75	22.29	21.21	21.41	923.77K
Mar 20, 2026	22.46	22.75	21.64	21.64	3.86M
Mar 19, 2026	21.91	22.86	21.71	22.43	823.39K
Mar 18, 2026	22.50	22.50	21.98	22.21	523.41K
Mar 17, 2026	22.52	23.16	22.32	22.59	598.84K
Mar 16, 2026	22.56	23.04	22.32	22.45	1.1M

Contact Details

Hayward, CA 94545

United States

https://www.arcusbio.com 510 694 6200

About Company

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Stock Peers

MANE

3.63+5.09%

Veradermics, Incorporated$74.99 AMAM

0.02+0.07%

Ambrx Biopharma Inc.$28.00 EVMN

-0.38-1.41%

Evommune, Inc.$26.63 ANRO

0.07+0.27%

Alto Neuroscience, Inc.$25.82 BHVN

0.32+3.16%

Biohaven Ltd.$10.44 DNA

1.04+15.57%

Ginkgo Bioworks Holdings, Inc.$7.72 BTX

0.11+1.50%

BlackRock Technology and Private Equity Term Trust$7.46 NUVB

0.15+3.19%

Nuvation Bio Inc.$4.85 ADCT

0.05+1.31%

ADC Therapeutics S.A.$3.86 ANVS

0.07+4.22%

Annovis Bio, Inc.$1.73

Company Overview

Arcus Biosciences, Inc. (NYSE:RCUS) closed at $23.20 USD, losing -$0.50 (-2.11%) from the previous close of $23.70. The stock is currently mid-range between its 52-week high and low $7.06 and $26.40. With a market capitalization of about $2.34 billion, Arcus Biosciences, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.86). Key stats such as the average daily volume over the past year has been around 1.10 million shares, volume is running light vs its 52-week average. Headquartered in Hayward, CA, Arcus Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Terry J. Rosen, the company employs approximately 627 people and listed since March 15, 2018. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Technical Performance

RCUS has shown sold momentum, gaining 3.05% over the past week and 33.27% over the past quarter, though year-to-date performance is down -7.89%. Short-term trend indicators are mixed aligned (SMA20 -3.9%, SMA50 -9.64%, SMA200 26.68%). The stock’s 14-day RSI is 43.33 (neutral), while the ATR of 1.24 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.98% below its high and over 200.62% above its low. Average 10-day trading volume of 714.57 thousand shares is below the 3-month average of 1.08 million, indicating normal recent market interest.

Valuation Metrics

Arcus Biosciences, Inc. trades at a P/E ratio of -6.97, slightly below the S&P 500 average, with a price-to-sales ratio of 9.34 and a price-to-book ratio of 3.9 trading at moderately above to book value. The P/FCF stands at -4.77, also above market averages.

Dividend & Fair Value

Arcus Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$16.89. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Arcus Biosciences, Inc. generated EPS of -$3.43 over the past year. Five-year average earnings growth is -10.2%. Wall Street analysts project EPS growth of 14.39% annually over the next five years. The latest quarter delivered EPS of -$1.27. The next quarter is forecast at -$1.09. Next year's EPS is expected at -$1.43. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 8 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $56.00 to $16.00. The high target offers 143.37% upside. The low target suggests -30.47% downside. The mean target is $34.56. This offers 50.2% upside. Arcus Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by -4.51%. The prior quarter beat by -93.41%. Over the last six quarters, Apple has recorded several small beats. These include 0.08% in August 08, 2024.

Shareholding & Insider Activity

Arcus Biosciences, Inc. has 106.43 million shares outstanding. The public float is 59.89 million shares, elevated short interest at 14.13% of float. This equals 9.83 million shares. The short ratio is 13.27 days. Institutional investors hold 103.45% of the float. Insiders own 34.73%. GILEAD SCIENCES, INC. holds 31.42 million shares, GILEAD SCIENCES INC has 13.91 million shares and ROSEN TERRY J has 2.19 million shares. Over the past six months, insider transactions show net selling. They sold 331.47 thousand shares across 27 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Arcus Biosciences generated $117.00M in revenue, or $1.58 per share. Gross margin was 86.32%, operating margin -290.60%, and net profit margin -262.39%. Returns are negative, with ROA at -28.04% and ROE at -66.45%.
On valuation metrics, Arcus Biosciences trades at a P/E of -6.97, P/S of 9.34 and P/B of 3.90. The current ratio is 4.36 and quick ratio is 4.36. Debt-to-equity is 0.16, supported by a cash flow-to-debt ratio of -4.87.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Arcus Biosciences posted revenue of $117.00M, down slightly from $112.00M in the prior quarter. Gross profit was $101.00M (margin 86.32%). Operating income was - $340.00M (margin -290.6%). Net income was- $307.00M (EPS - $4.15).
The company ended the quarter with $759.00M in cash and short-term investments, a total debt of $11.00M, and net debt of - $116.00M. Total assets were $1.10B, with equity of $462.00M. Financials further reflected weakness, with operating cash flow of - $306.00M, free cash flow of - $330.00M, and capital expenditures of - $24.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Arcus Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.39%, with price expected at $22.69 by April 28, 2026, within a range of $21.38 to $24.09 3-Month Outlook: Projected rise of 30.16%, reaching $29.95 by July 13, 2026, with a range of $28.68 to $31.31. 1-Year Outlook: Projected loss of -8.0%, with price at $21.17 by April 14, 2027, within a range of $19.77 to $22.72.

Key Takeaways

Arcus Biosciences, Inc. (NYSE:RCUS) shares are flat -7.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Arcus Biosciences, Inc. trading at a premium to the broader market with a P/E of -6.97. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $34.79, suggesting 51.2% upside. Our AI forecast model points to short-term weakness (-1.39% over two weeks), a medium-term rise (30.16% over three months), and a longer-term loss (-8.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Arcus Biosciences, Inc. (RCUS) stock price?

Arcus Biosciences, Inc. (NYSE: RCUS) stock price is $23.20 in the last trading session. During the trading session, RCUS stock reached the peak price of $23.74 while $22.96 was the lowest point it dropped to. The percentage change in RCUS stock occurred in the recent session was -2.11% while the dollar amount for the price change in RCUS stock was - $0.50.

RCUS's industry and sector of operation?

The NYSE listed RCUS is part of Biotechnology industry that operates in the broader Healthcare sector. Arcus Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RCUS?

Dr. Jonathan Yingling Ph.D.
Chief Scientific Officer
Dr. Juan Carlos Jaen Ph.D.
Co-Founder, Pres & Director
Dr. K. Christopher Garcia Ph.D.
Co-Founder & Member of Scientific Advisor
Dr. K. Christopher Garcia Ph.D.
Co-Founder & Member of Scientific Advisor
Holli Kolkey
Vice President of Corporation Communications
Dr. Stephen Young Ph.D.
Senior Vice President of Technology & Quantitative Biology
Mr. Robert C. Goeltz II
Principal Financial Officer & Chief Financial Officer
Dr. Terry J. Rosen Ph.D.
Co-Founder, Chairman & Chief Executive Officer
Ms. Jennifer A. Jarrett M.B.A.
Chief Operating Officer & Director
Ms. Carolyn C. Tang J.D.
Gen. Counsel & Corporation Sec.
Ms. Katherine Bock
Vice President of Investor Relations & Corporation Strategy
Dr. Dimitry S.A. Nuyten M.D., Ph.D.
Chief Medical Officer
Mr. Alexander Azoy
Chief Accounting Officer & Principal Accounting Officer

How RCUS did perform over past 52-week?

RCUS's closing price is 225.92% higher than its 52-week low of $7.06 where as its distance from 52-week high of $26.40 is -12.84%.

How many employees does RCUS have?

Number of RCUS employees currently stands at 627.

Link for RCUS official website?

Official Website of RCUS is: https://www.arcusbio.com

How do I contact RCUS?

RCUS could be contacted at phone 510 694 6200 and can also be accessed through its website. RCUS operates from 3928 Point Eden Way, Hayward, CA 94545, United States.

How many shares of RCUS are traded daily?

RCUS stock volume for the day was 300.34K shares. The average number of RCUS shares traded daily for last 3 months was 1.1M.

What is the market cap of RCUS currently?

The market value of RCUS currently stands at $2.34B with its latest stock price at $23.20 and 100.67M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	627
Beta	0.86
Sales or Revenue	$117.00M
5Y Sales Change%	5.553%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RCUS Company Profile and Key Details

Arcus Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics